Latest news with #PrescriptionDrugs
CNN
2 days ago
- Business
- CNN
In a deal with Trump, Europe gets an elusive agreement. But everyone's a little annoyed
Tariffs European Union Prescription drugsFacebookTweetLink Follow The United States and the European Union avoided the worst-case scenario: a damaging, all-out trade war between allies that threatened to raise prices on a large number of goods and slow two of the world's largest economies. The framework delivered a sense of relief for both sides – but few are cheering the arrangement itself. The agreement, which sets a 15% tariff on most European goods entering the United States, is higher than the 10% tariff Trump put in place on April 2 and significantly higher than the average of around 2% from before Trump's presidency. But it's significantly less than the enormous numbers Trump had been threatening if an agreement wasn't reached. A deal with the United States felt like an impossibility in late May. Frustrated by a lack of progress in negotiations with the 27-member European Union, Trump on May 24 told the world he was done talking to some of America's strongest allies. 'Our discussions with them are going nowhere!' Trump posted on Truth Social. 'I'm not looking for a deal,' he said later that day in the Oval Office. 'We've set the deal — it's at 50%.' The statement — and the shockingly high tariff threat — stunned European trade negotiators and rallied Europe's leaders into action. They quickly agreed to kick talks into high gear. Trump, who has taken a particular liking to European Commission President Ursula von der Leyen, was swayed after she called him to say the EU would commit to moving 'swiftly and decisively.' Trump soon backed off his threat and said negotiations would continue. But a deal between the United States and the European Union, one of America's top trading partners, had remained elusive for months. The two sides squabbled over America's insistence on high tariffs for steel and aluminum, looming tariffs on pharmaceuticals and the tariff floor for virtually all goods that the Trump administration appears set to raise to 15%. Negotiators were unable to come up with a resolution before the initial July 9 deadline — one of the reasons the Trump administration postponed the effective day for its 'reciprocal' tariffs to August 1. With just days to go before the extended deadline, while Trump was visiting Scotland, he met with van der Leyen and finalized a framework for an agreement — one that was thin on details, heavy on caveats, but was nevertheless a hard-sought relief for both sides. With the agreement in place, two of the world's largest economies avoided a potential economically crippling trade war. The United States held a 50% tariff threat over Europe's head, and Europe threatened America with strategic retaliatory tariffs that threatened to damage key US industries. Both sides appeared to embrace the fact that a deal was in place more than they celebrated it. 'We made it,' Trump said while announcing the deal with von der Leyen. 'It's going to work out really well.' 'I think we hit exactly the point we wanted to find,' von der Leyen said. 'Rebalance but enable trade on both sides. Which means good jobs on both sides of the Atlantic, means prosperity on both sides of the Atlantic and that was important for us.' Markets cheered, somewhat: Dow futures rose 150 points, or 0.3%, poised to open near record territory. S&P 500 futures gained 0.3% and Nasdaq futures were 0.4% higher. The United States and Europe 'seem to have avoided a self-destructive trade war for now in the biggest and deepest commercial and investment relationship the global economy knows,' said Jörn Fleck, senior director of the Atlantic Council's Europe Center. Nevertheless, the details remain murky. Europe will increase its investment in the United States by $600 billion and commit to buying $750 billion worth of US energy products. It eliminates tariffs on a variety of items, including aircraft and plane parts, semiconductors, generic drugs and some chemicals and agricultural products. Industries in the zero-tariff arrangement cheered. 'The zero-for-zero tariff regime will grow jobs, strengthen our economic security and provide a framework for U.S. leadership in manufacturing and safety,' Airlines for America said in a statement. But the 15% baseline tariff applies to most goods, so the EU member states – and American importers — will have to come to terms with the fact that higher tariffs will raise prices for European goods in America. 'Higher tariffs mean higher prices for US consumers—and that will seriously dent EU companies' bottom lines,' said Alex Altmann, vice president of the British Chamber of Commerce in Germany. 'EU companies aiming to stay competitive in the US market will think twice when deciding where to produce or assemble.' The agreement also deals another blow to Detroit automakers, which objected to a similar deal the Trump administration reached with Japan. The 15% auto tariff on EU cars imported to the United States undercuts the 25% tariff American automakers pay if their cars are built in Mexico. Although von der Leyen said pharmaceuticals were included in the early framework, she acknowledged that Trump may ultimately place higher tariffs on drugs imported to the United States, undercutting the agreement. Still, in the eyes of the hard-working negotiators — and for the sake of the global economy — a deal is better than no deal. Now comes the hard part: figuring out the details.
CNN
2 days ago
- Business
- CNN
In a deal with Trump, Europe gets an elusive agreement. But everyone's a little annoyed
Tariffs European Union Prescription drugsFacebookTweetLink Follow The United States and the European Union avoided the worst-case scenario: a damaging, all-out trade war between allies that threatened to raise prices on a large number of goods and slow two of the world's largest economies. The framework delivered a sense of relief for both sides – but few are cheering the arrangement itself. The agreement, which sets a 15% tariff on most European goods entering the United States, is higher than the 10% tariff Trump put in place on April 2 and significantly higher than the average of around 2% from before Trump's presidency. But it's significantly less than the enormous numbers Trump had been threatening if an agreement wasn't reached. A deal with the United States felt like an impossibility in late May. Frustrated by a lack of progress in negotiations with the 27-member European Union, Trump on May 24 told the world he was done talking to some of America's strongest allies. 'Our discussions with them are going nowhere!' Trump posted on Truth Social. 'I'm not looking for a deal,' he said later that day in the Oval Office. 'We've set the deal — it's at 50%.' The statement — and the shockingly high tariff threat — stunned European trade negotiators and rallied Europe's leaders into action. They quickly agreed to kick talks into high gear. Trump, who has taken a particular liking to European Commission President Ursula von der Leyen, was swayed after she called him to say the EU would commit to moving 'swiftly and decisively.' Trump soon backed off his threat and said negotiations would continue. But a deal between the United States and the European Union, one of America's top trading partners, had remained elusive for months. The two sides squabbled over America's insistence on high tariffs for steel and aluminum, looming tariffs on pharmaceuticals and the tariff floor for virtually all goods that the Trump administration appears set to raise to 15%. Negotiators were unable to come up with a resolution before the initial July 9 deadline — one of the reasons the Trump administration postponed the effective day for its 'reciprocal' tariffs to August 1. With just days to go before the extended deadline, while Trump was visiting Scotland, he met with van der Leyen and finalized a framework for an agreement — one that was thin on details, heavy on caveats, but was nevertheless a hard-sought relief for both sides. With the agreement in place, two of the world's largest economies avoided a potential economically crippling trade war. The United States held a 50% tariff threat over Europe's head, and Europe threatened America with strategic retaliatory tariffs that threatened to damage key US industries. Both sides appeared to embrace the fact that a deal was in place more than they celebrated it. 'We made it,' Trump said while announcing the deal with von der Leyen. 'It's going to work out really well.' 'I think we hit exactly the point we wanted to find,' von der Leyen said. 'Rebalance but enable trade on both sides. Which means good jobs on both sides of the Atlantic, means prosperity on both sides of the Atlantic and that was important for us.' Markets cheered, somewhat: Dow futures rose 150 points, or 0.3%, poised to open near record territory. S&P 500 futures gained 0.3% and Nasdaq futures were 0.4% higher. The United States and Europe 'seem to have avoided a self-destructive trade war for now in the biggest and deepest commercial and investment relationship the global economy knows,' said Jörn Fleck, senior director of the Atlantic Council's Europe Center. Nevertheless, the details remain murky. Europe will increase its investment in the United States by $600 billion and commit to buying $750 billion worth of US energy products. It eliminates tariffs on a variety of items, including aircraft and plane parts, semiconductors, generic drugs and some chemicals and agricultural products. Industries in the zero-tariff arrangement cheered. 'The zero-for-zero tariff regime will grow jobs, strengthen our economic security and provide a framework for U.S. leadership in manufacturing and safety,' Airlines for America said in a statement. But the 15% baseline tariff applies to most goods, so the EU member states – and American importers — will have to come to terms with the fact that higher tariffs will raise prices for European goods in America. 'Higher tariffs mean higher prices for US consumers—and that will seriously dent EU companies' bottom lines,' said Alex Altmann, vice president of the British Chamber of Commerce in Germany. 'EU companies aiming to stay competitive in the US market will think twice when deciding where to produce or assemble.' The agreement also deals another blow to Detroit automakers, which objected to a similar deal the Trump administration reached with Japan. The 15% auto tariff on EU cars imported to the United States undercuts the 25% tariff American automakers pay if their cars are built in Mexico. Although von der Leyen said pharmaceuticals were included in the early framework, she acknowledged that Trump may ultimately place higher tariffs on drugs imported to the United States, undercutting the agreement. Still, in the eyes of the hard-working negotiators — and for the sake of the global economy — a deal is better than no deal. Now comes the hard part: figuring out the details.
New York Times
18-07-2025
- Health
- New York Times
Health Insurers Are Denying More Drug Claims, Data Shows
Prescription drug denials by private insurers in the United States jumped 25 percent from 2016 to 2023, according to a new analysis of more than four billion claims, a practice that has contributed to rising public outrage about the nation's private health insurance system. The report, compiled for The New York Times by the medical data company Komodo Health, shows that denial rates rose from 18.3 percent to 22.9 percent. The rejections went up across many major health plans, including the country's largest private insurer, UnitedHealthcare. The data offers a rare look into the largely hidden world of rejected insurance claims. While some government-funded health plans are required to publish their denial rates, most private insurers keep that information confidential. Komodo draws from private databases that collect denial details from pharmacies, insurers and intermediaries. Claim denials are 'quite opaque, and a lot of decisions are made by private actors,' said Dr. Aaron Schwartz, a health economist at the University of Pennsylvania. 'There are legitimate questions about whether they are appropriate.' Widespread resentment toward health insurers boiled over last December after the murder of UnitedHealthcare's chief executive, Brian Thompson. Doctors and patients alike took to social media to share stories of insurers' refusal to pay for what they said was needed medical care. Experts who have studied denials said the skyrocketing costs of popular new weight loss medications and greater automation of the claims process with artificial intelligence may have contributed to the rising rejection rates. Drug denials by private plans have increased Denial rates were calculated using 4.5 billion claims from commercial health plans Source: Komodo Health By Sarah Kliff Denials went up at five major health plans Source: Komodo Health By: Sarah Kliff Want all of The Times? Subscribe.
CNN
10-07-2025
- CNN
Cyanide, an affair, and a jailhouse murder plot: The case against a Colorado dentist accused of poisoning his wife
Crime Prescription drugsFacebookTweetLink Follow Angela Craig was complaining of severe headaches and dizziness. She had been to the hospital three times in 10 days, yet doctors in Colorado couldn't explain what was causing her illness. 'I feel drugged,' she texted her husband, James Craig, during her first hospitalization. She told him the only thing she consumed that morning was her protein shake, according to court records. Three hours into her third hospital visit, the mother of six began seizing and was transferred unresponsive to the hospital's intensive care unit. Three days later, on March 18, 2023, 43-year-old Craig was declared brain dead, court records show. More than two years after her death, her dentist husband is due to stand trial for her murder. Jury selection begins Thursday. A probable cause affidavit containing more than 50 pages of evidence investigators compiled against James Craig includes witness accounts, screenshots of text messages and computer search histories, and the discovery of a secret email account used to order a multitude of poisons and carry out an affair with another woman. Between Angela Craig's death and the start of her husband's trial, the defendant has cycled through a carousel of lawyers – including one who withdrew due to Craig's alleged actions and another accused of setting fire to his own home – and the dentist himself has been accused of plotting a jailhouse murder against the case's lead investigator. Craig has pleaded not guilty to six felony charges, including first-degree murder, solicitation to commit first-degree murder, solicitation to commit tampering with physical evidence, and solicitation to commit perjury. He faces life in prison without the possibility of parole if convicted of murder. James Craig's dental partner, Ryan Redfearn, was the first person to sound the alarm to authorities that Angela could have been poisoned, according to the affidavit. While he was en route to the hospital the day of Angela's final hospitalization, a colleague called Redfearn saying an office manager had seen a package of potassium cyanide delivered for Craig to the office days prior, the affidavit says. When he arrived, Redfearn alerted a nurse about the package, telling her there would be no medical reason for a dentist's office to need potassium cyanide. The nurse subsequently contacted law enforcement, according to the document. Craig called his colleague later that night asking if he had spoken with the medical staff. Redfearn said he had and that he knew about the package, the affidavit says. Craig allegedly tried to fabricate a story before eventually admitting to ordering the potassium cyanide, but said his wife had asked him to buy it – purportedly the first of several unsubstantiated claims that she was suffering from suicidal ideations. By that point in the conversation, Redfearn had only one more thing to tell his colleague, the affidavit says: 'Stop talking and get a lawyer.' Michelle Redfearn, Ryan Redfearn's wife, has previously declined CNN's requests for comment, saying the couple expects to be called to testify at trial. Text messages between Craig and his wife during her hospitalizations suggest she may have suspected she was being drugged leading up to her death, according to the affidavit. 'It feels more like I feel when I take heavy meds and everything adjusts and moves slowly,' she texted Craig during her first hospitalization. When she said she felt drugged, her husband replied, 'Given our history, I know that must be triggering.' 'Just for the record, I didn't drug you.' One of Angela Craig's sisters told investigators James Craig had drugged his wife several years prior, so she wouldn't be able to stop him from attempting suicide, the affidavit says. And Craig's wife directly accused him of poisoning her when she was discharged from her second hospital stay, the dental employee who saw the potassium cyanide package told investigators, according to the affidavit. Angela's cause of death was acute cyanide and tetrahydrozoline poisoning, with subacute arsenic poisoning listed as a significant condition, according to the coroner's report. Investigators later discovered an email account that had only been accessed using a computer in an exam room at Craig's dental practice, according to the affidavit. Within the account history, investigators uncovered numerous searches related to poisons, including 'how many grams of pure arsenic will kill a human,' and 'Is Arsenic Detectable in Autopsy?' along with YouTube searches for 'how to make poison,' and 'Top 5 Undetectable Poisons That Show No Signs of Foul Play,' the affidavit says. Investigators found the account had been used to place online orders for some of the poisons from those searches, including arsenic and potassium cyanide, according to the affidavit, which provided a timeline. Receipts showed the arsenic was purchased on February 24 and delivered to the Craig home on March 4, just two days before Angela Craig's first hospitalization. The potassium cyanide was ordered on March 8 and delivered to James Craig's office March 13 – the same date the dental employee saw the open package of potassium cyanide there. Investigators also uncovered 'sexually explicit' email exchanges between Craig and a woman named Karin Cain who traveled from Texas to Colorado to visit Craig while his wife was hospitalized, the affidavit says. In an exclusive interview with ABC News in 2023, Cain said she met Craig at a dental convention that February and he told her he was amid a divorce. 'If I had known what was true, I would not have been with this person,' Cain said. Cain denied investigators' assertions that she was part of Craig's motive to allegedly kill his wife, saying they'd only been together for three weeks at the time. Since his arrest, Craig has cycled through a litany of lawyers in the case, at times causing court delays. He initially hired a team of three attorneys to defend him against the charges. In May 2024, Craig replaced them with well-known Denver attorney Harvey Steinberg. But November 21, 2024, the day jury selection for the rescheduled trial was set to begin, Steinberg abruptly requested to withdraw from the case, citing two rules of professional conduct, according to prosecutors. The first states, 'The client persists in a course of action involving the lawyer's services that the lawyer reasonably believes is criminal or fraudulent,' and the second says, 'The client insists upon taking action that the lawyer considers repugnant or with which the lawyer has a fundamental disagreement.' Steinberg has not responded to requests for comment. Craig's next attorneys, Lisa Moses and Robert Werking, were appointed for him by the court and the trial was rescheduled for July. But one of those lawyers, Werking, soon found himself in legal trouble: On June 14, he was cited for a misdemeanor weapons violation, court records show. Then on June 29, he was arrested for felony fourth-degree arson at his home, according to Arapahoe County Sheriff's Office spokesperson John Bartmann. When deputies responded to the house fire, Werking was sitting on the porch, Bartmann said. Last week, Werking filed a motion to withdraw from Craig's case, which was granted on July 2, prosecutors said. To defend himself against his own alleged crimes, Werking retained Liz Delay and David Beller – two of the attorneys who originally represented Craig. 'Being a defense lawyer necessarily means bearing the burden of living at all times in other people's trauma,' Beller said in a statement to CNN, adding that Werking is seeking mental health treatment. 'I'm asking the public give him and others like him grace, compassion, and withhold judgment, knowing that the constant fight for justice takes out soldiers, but others are always lined up to ensure that constitutional protections are spared for no one.' Werking has not entered pleas. Moses remains as counsel for Craig, and an additional attorney, Ashley Whitham, has also joined his defense team. One day after Steinberg withdrew from the case, prosecutors added a solicitation to commit murder charge and an additional solicitation to commit perjury charge against Craig, alleging he plotted to kill four people from behind bars while awaiting trial. 'The worst, dirtiest detective in the world is on my case. Her name is Bobbi Olson, we have to discredit her,' the defendant wrote in a letter from jail, referring to the lead detective investigating his wife's murder. Prosecutors introduced the letter during a February preliminary hearing on the new charges. Craig tried to convince a fellow inmate, Nathaniel Harris, to kill Olson, along with an officer referred to in court only as Officer Hillstrand, who investigators say they have not been able to identify, and two other inmates housed in the detention facility's medical unit with Craig, prosecutors said. Craig also wrote letters to Harris' ex-wife, Kasiani 'Kasi' Konstantinidis, in an attempt to convince her to 'fabricate evidence,' according to prosecutors. Law enforcement intercepted one of the letters during a cell search and testified during the hearing that Craig offered 'essentially a blank check' for Konstantinidis to fabricate texts, phone records and photographs to back up a fake story about her being friends with Angela Craig. Another investigator testified that they retrieved a second letter to Konstantinidis – unopened – which indicated Craig believed his case hinged on 'being able to find someone to say Angela was suicidal.' Craig allegedly wanted Konstantinidis to sell the story not just to the district attorney's office, but also to his own attorney at the time, Steinberg, who then withdrew from the case.
Yahoo
26-05-2025
- Business
- Yahoo
Diet Pills to Surpass USD 4.48 Billion By 2032 Owing to Rising Number of People with Obesity and Increasing Appetite for Non-Invasive Solutions to Weight Management
U.S. Diet Pills Market size to be valued at USD 1.08 Billion in 2032, Project at 12.90% CAGR, Rising Consumption of Prescription Drugs and Increase in the Sales of OTC in Pharmacies and E-commerce. Austin, May 26, 2025 (GLOBE NEWSWIRE) -- Diet Pills Market Size & Growth Analysis: According to SNS Insider, the global Diet Pills Market size stood at USD 1.83 billion in 2024 and is estimated to reach USD 4.48 billion by 2032, with a CAGR of 11.87% from 2025 to 2032. Rising incidence of obesity and sedentary lifestyle on a global level is driving the need for easy to use and efficient weight management methods. Increasing consumer preference for non-surgical non-invasive weight reduction procedures along with growing concern of health hazards associated with obesity is the prediction that is contributing to this a Sample Report of Diet Pills Market@ U.S. Diet Pills Market is estimated to be USD 0.44 billion in 2024 and is projected to exhibit a CAGR of 12.90% over the forecast period (2025-2032). In the U.S., the high uptake of prescription and metabolism-enhancing weight loss drugs, as well as growing OTC demand in drug stores and retail outlets, are driving growth in the U.S. market. Market Overview Diet pills are increasingly growing contoured on the background of increasing trend of obesity, diabetes, and other metabolic diseases worldwide. Worldwide estimates from recent global health data indicate that >40% of adults are overweight or obese, requiring immediate, effective weight-loss interventions. Diet pills present an attractive option to surgery and vigorous exercise. The market too has gained traction with the expansion of healthcare access and with the introduction of digital health platforms, which provides for online consultations, prescriptions and consumer awareness about weight-loss treatments. The introduction of product innovations, including appetite suppressant/metabolism booster combination products, non-stimulant options or plant-based capsules, has increased consumer use in different demographic target groups, including the young and those in whom there may be contraindications to conventional treatment. In an era of preventive health and wellness, diet pills are included in overall wellness programs. Major Players Analysis Listed in this Report are: Iovate Health Sciences Inc. Zoller Laboratories Cortislim Nanjing Chang'ao Pharmaceutical Co. Vivus Inc. Orexigen Therapeutics GlaxoSmithKline Pharmaceuticals Ltd. Gelesis Inc. Herbalife International Amway Corp. and others in the final report Diet Pills Market Report Scope Report Attributes Details Market Size in 2024 US$ 1.83 billion Market Size by 2032 US$ 4.48 billion CAGR CAGR of 11.87% From 2025 to 2032 Base Year 2023 Forecast Period 2025-2032 Historical Data 2021-2023 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: In 2024, prescription-based drugs held the largest share of the market at 62%, owing to clinical efficacy, regulatory backing, and physician trust in managing moderate to severe obesity. These drugs are often the first line of treatment for individuals with comorbidities like diabetes and hypertension. On the other hand, herbal remedies have emerged as the fastest-growing product segment. Their rise is driven by a global trend toward natural and plant-based healthcare solutions, especially among younger consumers and those wary of synthetic chemicals. By Application: Appetite-controlling pills accounted for around 48% of the market share in 2024, making them the dominant application. These pills are preferred for their ability to help regulate food intake and reduce binge-eating behaviors, which is common in sedentary urban populations. However, metabolism-boosting pills are seeing the highest growth rate. Consumers increasingly favor them for their perceived ability to burn calories efficiently, especially when combined with minimal physical activity, which aligns with the busy lifestyles of working professionals. By Distribution Channel: Retail pharmacies led the distribution channels with 53% of the market share in 2024. These outlets are accessible and trusted by consumers, offering both OTC and prescription-based diet pills. Meanwhile, hospital pharmacies are growing rapidly as healthcare providers increasingly prescribe weight loss medications in clinical settings. The credibility and availability of post-consultation guidance in hospitals make them the fastest-growing channel. Need Any Customization Research on Diet Pills Market, Enquire Now@ Diet Pills Market Segmentation By Product Type Prescription-Based Drugs Over-the-Counter Drugs Herbal Supplements By Application Metabolism Raising Pills Fat Blocking Pills Appetite Controlling Pills By Distribution Channel Hospital Pharmacy Retail Pharmacy Drug Stores Regional Analysis Asia Pacific dominated the global diet pills market in 2024, driven by rising obesity rates in densely populated countries like China and India, growing disposable income, and rapid urbanization. The regional market benefits from both traditional medicine integration and increasing acceptance of Western pharmacological treatments. North America emerged as the second-largest regional market, fueled by the high prevalence of obesity, strong pharmaceutical infrastructure, and widespread insurance coverage for prescription weight-loss medications. The U.S. market, in particular, is witnessing a surge in consumer spending on lifestyle-enhancing drugs and an increase in online pharmacy adoption. Recent Developments In March 2025, Eli Lilly reported successful mid-stage trials for orforglipron, its once-daily oral weight loss drug. The pill demonstrated significant weight reduction, potentially rivaling injectable GLP-1 therapies. In April 2025, Pfizer halted development of its oral weight-loss candidate, danuglipron, due to adverse side effects in Phase 2 trials, indicating market risks in oral anti-obesity drug development. In November 2024, Nature's Way released SlimBiotic Naturals, an herbal diet supplement containing green coffee bean extract and garcinia cambogia, entering the fast-growing plant-based pill market. In September 2024, PhenQ introduced PhenQ PM, a nighttime fat-burning formula to complement its popular daytime version, appealing to 24-hour weight management consumers. Statistical Insights and Trends Reporting Over 1 billion adults were overweight, with more than 650 million classified as obese worldwide. This demographic forms the core consumer base for diet pills. North America accounted for over 40% of global prescription diet pill sales, driven by advanced healthcare infrastructure and favorable regulatory support. The number of diet pills sold annually is projected to nearly triple from 1.2 billion units in 2020 to over 3.4 billion units by 2032, with strong demand from Asia Pacific. Consumer out-of-pocket expenditure on weight-loss supplements and prescription pills accounted for 65% of total spending in emerging economies due to limited insurance coverage. Online sales of diet pills witnessed a 45% year-on-year growth, especially in urban markets, due to increasing e-commerce penetration and discreet delivery a Single-User PDF of Diet Pills Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Obesity and Overweight Prevalence (2024), by Region 5.2 Diet Pills Consumption and Usage Trends (2024), by Region 5.3 Prescription vs. OTC Diet Pills Trends (2021–2032) 5.4 Consumer Spending on Weight Management Products, by Region (2024) 5.5 Internet & E-Commerce Sales Trends for Diet Pills (2021–2024) 5.6 Regulatory Trends and Product Approvals (Recent Years) 6. Competitive Landscape 7. Diet Pills Market by Product Type 8. Diet Pills Market by Application 9. Diet Pills Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Related Reports U.S. Anti-Obesity Drugs Market Set to Soar, Reaching $10.28 Billion by 2032 at 24.07% CAGR. Global Weight Loss Drugs Market to Skyrocket to $50.26 Billion by 2032, Growing at 43.73% CAGR. Weight Loss Supplements Market to Hit $161.03 Billion by 2030, Growing at 16.9% CAGR. Weight Loss Devices Market Forecasted to Reach $8.50 Billion by 2032, Growing at 6.60% CAGR. About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
